



BRIAN SANDOVAL
Governor

STATE OF NEVADA
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 E. William Street, Suite 101
Carson City, Nevada 89701
(775) 684-3600

ROMAINE GILLILAND
Director

LAURIE SQUARTSOFF
Administrator

NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD

AGENDA

Date of Posting: October 2, 2014

Date of Meeting: Thursday, October 23, 2014 at 5:30 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board (DUR).

Place of Meeting: Silver Legacy
Silver/Gold Room
407 N Virginia St
Reno, Nevada 89501

AGENDA

- 1. Call to Order and Roll Call**
- 2. Public Comment on Any Matter on the Agenda**
- 3. Administrative**
 - a. **For Possible Action:** Review and Approve Meeting Minutes from July 24, 2014.
 - b. Status Update by DHCFP
 - i. Public Comment
 - ii. Program updates
 1. Health Care Reform
- 4. Presentation and Discussion of Nevada's Prescription Monitoring Program**
 - a. Jenine M. Davis, Pre-Criminal Intervention Officer, Controlled Substance Abuse Prevention Task Force
- 5. Clinical Presentations**
 - a. **For Possible Action:** Discussion and proposed adoption of updated clinical prior authorization criteria for sofosbuvir (Sovaldi®).
 1. Public comment on proposed clinical prior authorization criteria.

2. Presentation of utilization and clinical information.
 3. Discussion by the Board and review of utilization data.
 4. Proposed adoption of updated prior authorization criteria.
- b. **For Possible Action:** Discussion and proposed adoption of updated prior authorization criteria for apixaban (Eliquis®)
1. Public Comment on proposed clinical prior authorization criteria.
 2. Presentation of utilization and clinical information.
 3. Discussion by the Board and review of utilization data.
 4. Proposed adoption of updated prior authorization criteria.
- c. **For Possible Action:** Discussion and proposed adoption of updated clinical prior authorization criteria for the immunomodulator class of medication.
1. Public comment on proposed clinical prior authorization criteria.
 2. Presentation of utilization and clinical information.
 3. Discussion by Board and review of utilization data.
 4. Proposed adoption of updated prior authorization criteria.
- d. **For Possible Action:** Discussion and proposed adoption of updated clinical prior authorization criteria for transdermal fentanyl.
1. Public comment on proposed clinical prior authorization criteria.
 2. Presentation of utilization and clinical information.
 3. Discussion by Board and review of utilization data.
 4. Proposed adoption of updated prior authorization criteria.

6. DUR Board Requested Reports

- a. Report on Top 10 Black Box warning medications:
1. Public comment on Black Box warnings.
 2. Discussion by the Board and review of utilization data.
- b. Report on controlled substance utilization and trends.
1. Public comment on controlled substance utilization and trends.
 2. Discussion by the Board and review of utilization data.
- c. Report on psychotropic drug use in children.
1. Public comment on psychotropic drug use in children.
 2. Discussion by the Board and review of utilization data.
- d. Report on buprenorphine and buprenorphine/naloxone use.
1. Public comment on buprenorphine and buprenorphine/naloxone use.
 2. Discussion by the Board and review of utilization data.

- e. Report on Nevada Medicaid Lock-in Program
 - 1. Public comment on Lock-in Program.
 - 2. Discussion by the Board and review of utilization data.
- f. Report on Asthma treatment utilization.
 - 1. Public comment on asthma treatment utilization.
 - 2. Discussion by the Board and review of utilization data.
- g. Report on Tussionex Utilization.
 - 1. Public comment on Tussionex Utilization.
 - 2. Discussion by the Board and review of utilization data.

7. Standard DUR Reports

- a. Review of Prescribing/Program Trends.
 - 1. Top 10 Therapeutic Classes for Q3 2013, Q4 2013, and Q1 2014 (by Payment and by Claims).
 - 2. Top 50 Drugs of Q3 2013, Q4 2013, and Q1 2014 (by Payment and by Claims).
- b. Concurrent Drug Utilization Review (ProDUR)
 - 1. Review of Q3 2013, Q4 2013, and Q1 2014.
 - 2. Review of Top Encounters by Problem Type.
- c. Retrospective Drug Utilization Review (RetroDUR)
 - 1. Public comment on Retro DUR.
 - 2. Status of previous quarter.
 - 3. Status of current quarter.
 - 4. Review and discussion of responses.

8. Closing Discussion

- a. Public comments on any subject.
- b. Date and location of the next meeting.
 - 1. Discussion of the time of the next meeting.
- c. Adjournment.

No action may be taken on a matter raised under any item of the agenda until the matter itself has been specifically included on the agenda as an item upon which action can be taken.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to 5 minutes per person or business entity.

This notice and agenda have been posted at www.dhcfp.nv.gov and <http://admin.nv.gov/> .

Notice of this meeting and items for discussion will be available on or after the date of this notice at the DHCFP Web site (dhcfp.nv.gov); Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the follow locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, items for discussion will be mailed to you. Requests and/or written comments on the items for discussion may be sent to the Division of Health Care Financing and Policy, Attention Rita Mackie, 1100 E. William Street, Suite 101, Carson City, NV 89701.

All persons that have requested in writing to receive the Public Hearings Agenda have been duly notified by mail or e-mail.

Note: We are pleased to make reasonable accommodations for members of the public who are physically challenged and wish to attend the meeting. If special arrangements for the meeting are necessary, please notify the Division of Health Care Financing and Policy, in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701, or call Rita Mackie at (775) 684-3681, as soon as possible, or e-mail at rmackie@dhcfp.nv.gov
